MYGN
Price
$21.32
Change
-$0.08 (-0.37%)
Updated
Mar 28, 6:59 PM EST
34 days until earnings call
PACB
Price
$3.75
Change
+$0.03 (+0.81%)
Updated
Mar 28, 6:59 PM EST
34 days until earnings call
Ad is loading...

Compare predictions MYGN vs PACB

Header iconMYGN vs PACB Comparison
Open Charts MYGN vs PACBBanner chart's image
Myriad Genetics
Price$21.32
Change-$0.08 (-0.37%)
Volume$380.86K
CapitalizationN/A
Pacific Biosciences of California
Price$3.75
Change+$0.03 (+0.81%)
Volume$3.77M
CapitalizationN/A
View a ticker or compare two or three
MYGN vs PACB Comparison Chart

Loading...

MYGNDaily Signal changed days agoGain/Loss if shorted
 
Show more...
PACBDaily Signal changed days agoGain/Loss if shorted
 
Show more...
VS
MYGN vs. PACB commentary
Mar 29, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MYGN is a Sell and PACB is a StrongBuy.

COMPARISON
Comparison
Mar 29, 2024
Stock price -- (MYGN: $21.32 vs. PACB: $3.75)
Brand notoriety: MYGN and PACB are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: MYGN: 97% vs. PACB: 79%
Market capitalization -- MYGN: $1.92B vs. PACB: $1B
MYGN [@Medical Specialties] is valued at $1.92B. PACB’s [@Medical Specialties] market capitalization is $1B. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $7.27B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MYGN’s FA Score shows that 1 FA rating(s) are green whilePACB’s FA Score has 0 green FA rating(s).

  • MYGN’s FA Score: 1 green, 4 red.
  • PACB’s FA Score: 0 green, 5 red.
According to our system of comparison, MYGN is a better buy in the long-term than PACB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MYGN’s TA Score shows that 5 TA indicator(s) are bullish while PACB’s TA Score has 4 bullish TA indicator(s).

  • MYGN’s TA Score: 5 bullish, 4 bearish.
  • PACB’s TA Score: 4 bullish, 2 bearish.
According to our system of comparison, PACB is a better buy in the short-term than MYGN.

Price Growth

MYGN (@Medical Specialties) experienced а -4.39% price change this week, while PACB (@Medical Specialties) price change was -2.34% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was +0.84%. For the same industry, the average monthly price growth was -0.26%, and the average quarterly price growth was +4.27%.

Reported Earning Dates

MYGN is expected to report earnings on May 02, 2024.

PACB is expected to report earnings on May 02, 2024.

Industries' Descriptions

@Medical Specialties (+0.84% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
A.I.dvisor published
a Summary for MYGN with price predictions.
OPEN
A.I.dvisor published
a Summary for PACB with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
MYGN($1.92B) has a higher market cap than PACB($1.01B). MYGN YTD gains are higher at: 11.390 vs. PACB (-61.774). MYGN has higher annual earnings (EBITDA): -197.4M vs. PACB (-277.28M). PACB has more cash in the bank: 631M vs. MYGN (141M). MYGN has less debt than PACB: MYGN (152M) vs PACB (934M). MYGN has higher revenues than PACB: MYGN (753M) vs PACB (201M).
MYGNPACBMYGN / PACB
Capitalization1.92B1.01B191%
EBITDA-197.4M-277.28M71%
Gain YTD11.390-61.774-18%
P/E RatioN/AN/A-
Revenue753M201M375%
Total Cash141M631M22%
Total Debt152M934M16%
FUNDAMENTALS RATINGS
MYGN vs PACB: Fundamental Ratings
MYGN
PACB
OUTLOOK RATING
1..100
5152
VALUATION
overvalued / fair valued / undervalued
1..100
96
Overvalued
99
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9697
PRICE GROWTH RATING
1..100
5395
P/E GROWTH RATING
1..100
180
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MYGN's Valuation (96) in the Biotechnology industry is in the same range as PACB (99). This means that MYGN’s stock grew similarly to PACB’s over the last 12 months.

MYGN's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as PACB (100). This means that MYGN’s stock grew similarly to PACB’s over the last 12 months.

MYGN's SMR Rating (96) in the Biotechnology industry is in the same range as PACB (97). This means that MYGN’s stock grew similarly to PACB’s over the last 12 months.

MYGN's Price Growth Rating (53) in the Biotechnology industry is somewhat better than the same rating for PACB (95). This means that MYGN’s stock grew somewhat faster than PACB’s over the last 12 months.

MYGN's P/E Growth Rating (1) in the Biotechnology industry is significantly better than the same rating for PACB (80). This means that MYGN’s stock grew significantly faster than PACB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MYGNPACB
RSI
ODDS (%)
N/A
Bullish Trend 1 day ago
85%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
73%
Bullish Trend 1 day ago
71%
Momentum
ODDS (%)
Bullish Trend 1 day ago
73%
N/A
MACD
ODDS (%)
Bearish Trend 4 days ago
81%
Bullish Trend 1 day ago
77%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
79%
Bearish Trend 1 day ago
87%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
79%
Bearish Trend 1 day ago
87%
Advances
ODDS (%)
Bullish Trend 9 days ago
78%
Bullish Trend 1 day ago
78%
Declines
ODDS (%)
Bearish Trend 1 day ago
79%
Bearish Trend 4 days ago
86%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
82%
N/A
Aroon
ODDS (%)
Bullish Trend 1 day ago
82%
Bearish Trend 1 day ago
84%
View a ticker or compare two or three
Ad is loading...
MYGNDaily Signal changed days agoGain/Loss if shorted
 
Show more...
PACBDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
NBHRX13.430.04
+0.30%
Neuberger Berman Equity Income R3
JHTCX17.46N/A
N/A
JPMorgan Hedged Equity 3 C
VDSCX18.30N/A
N/A
Victory Diversified Stock C
AFOYX15.62N/A
N/A
Ariel Focus Institutional
FBALX28.85-0.01
-0.03%
Fidelity Balanced

MYGN and

Correlation & Price change

A.I.dvisor indicates that over the last year, MYGN has been loosely correlated with RVTY. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if MYGN jumps, then RVTY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MYGN
1D Price
Change %
MYGN100%
-0.37%
RVTY - MYGN
51%
Loosely correlated
-0.39%
TWST - MYGN
41%
Loosely correlated
-0.49%
CERS - MYGN
40%
Loosely correlated
+5.59%
BIO - MYGN
39%
Loosely correlated
-1.06%
CRL - MYGN
39%
Loosely correlated
+0.59%
More

PACB and

Correlation & Price change

A.I.dvisor indicates that over the last year, PACB has been loosely correlated with MASI. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if PACB jumps, then MASI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PACB
1D Price
Change %
PACB100%
+0.81%
MASI - PACB
58%
Loosely correlated
+1.64%
TWST - PACB
56%
Loosely correlated
-0.49%
IQV - PACB
46%
Loosely correlated
+0.13%
EXAS - PACB
46%
Loosely correlated
+3.26%
ILMN - PACB
45%
Loosely correlated
-0.98%
More